Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma Journal Article


Authors: Minasian, L. M.; Szatrowski, T. P.; Rosenblum, M.; Steffens, T.; Morrison, M. E.; Chapman, P. B.; Williams, L.; Nathan, C. F.; Houghton, A. N.
Article Title: Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-α and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma
Abstract: Hemorrhagic tumor necrosis is an inflammatory event that leads to selective destruction of malignant tissues, with both potentially toxic and beneficial consequences. A pilot clinical trial was undertaken combining tumor necrosis factor-α (TNF-α) with the monoclonal antibody R24 (MoAb R24) against GD3 ganglioside in patients with metastatic melanoma. Patients received MoAb R24 to recruit leukocytes to the tumor followed by low doses of recombinant TNF-α to activate leukocytes. Eight patients were treated and seven patients had mild toxicity. One patient with extensive metastatic melanoma developed tumor lysis syndrome within hours after treatment with almost complete necrosis of bulky tumors in multiple visceral sites. To our knowledge, this is the first documented case of hemorrhagic tumor necrosis in a patient with metastatic cancer in multiple visceral sites.
Keywords: adult; controlled study; aged; human cell; cancer immunotherapy; melanoma; lung toxicity; antineoplastic combined chemotherapy protocols; necrosis; inflammatory cell; monoclonal antibody; tumor lysis syndrome; gastrointestinal toxicity; hypotension; cancer regression; antibodies, monoclonal; recombinant tumor necrosis factor; recombinant proteins; neutrophils; lymphoproliferative disease; drug therapy; urticaria; tumor necrosis factor; bleeding tendency; tetradecanoylphorbol acetate; cancer antibody; gangliosides; middle age; tumor necrosis; n-formylmethionine leucyl-phenylalanine; human; male; female; priority journal; article; monoclonal antibody r24; support, u.s. gov't, p.h.s.
Journal Title: Blood
Volume: 83
Issue: 1
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 1994-01-01
Start Page: 56
End Page: 64
Language: English
PROVIDER: scopus
PUBMED: 8274754
DOI: 10.1182/blood.V83.1.56.56
DOI/URL:
Notes: Export Date: 14 January 2019 -- Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Marc Rosenblum
    424 Rosenblum
  2. Paul Chapman
    326 Chapman
  3. Alan N Houghton
    364 Houghton